Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Why Is Biogen (BIIB) Stock Up Today?
10:16am, Monday, 14'th Nov 2022
Biogen (NASDAQ: BIIB ) stock is rising higher on Monday after Roche's (OTCMKTS: RHHBY ) Alzheimer's drug didn't perform well in a clinical trial. Roche has been developing a drug to treat Alzheimer's
What's Going On With Biogen Stock Today? - Biogen (NASDAQ:BIIB)
09:48am, Monday, 14'th Nov 2022
Biogen Inc (NASDAQ: BIIB) shares are trading higher Monday after competitor Roche's Alzheimer's candidate did not meet its primary endpoint in recent studies.
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
09:17am, Monday, 14'th Nov 2022
Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled. The post Roche's Alzheimer's Drug Fails In Phase 3; Here's The
Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemab
06:41am, Monday, 14'th Nov 2022
Biogen Inc. shares BIIB, -0.43% rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer's disease failed to meet its main goal. German-listed s
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
10:40am, Thursday, 10'th Nov 2022
Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements. The post Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles app
Biogen names former Sanofi chief as new CEO, shares rise
08:08am, Thursday, 10'th Nov 2022
Biogen Inc. BIIB, -1.35% stock rose 1% in premarket trades on Thursday after Christopher A. Viehbacher was named president and chief executive officer and a member of the board, effective Nov. 14.
BIIB vs. RGEN: Which Stock Is the Better Value Option?
12:49pm, Monday, 07'th Nov 2022
BIIB vs. RGEN: Which Stock Is the Better Value Option?
Is Biogen Poised for a Bull Run?
09:30am, Thursday, 03'rd Nov 2022
Biogen has been a market-beating stock this year, but can that trend continue?
Trading Ideas On The Upcoming CTAD 2022 Conference
03:27pm, Wednesday, 02'nd Nov 2022
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie
Biogen: Second Time's A Charm
12:37am, Tuesday, 01'st Nov 2022
Biogen appears set to obtain approval of a 2nd Alzheimer's drug. Lecanemab is far better received by the market with total peak sales forecasted at up to $14 billion with Biogen sharing 50% of the pro
Deal Activity Could Jumpstart Biotechnology
11:35pm, Monday, 31'st Oct 2022
Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID
Biogen: Super-Strong Momentum In A Defensive Sector
02:51pm, Monday, 31'st Oct 2022
Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. The latest positive readout on LECANEMAB, its second Alzheimer's drug likely to get FDA
10 Stocks Turned $10,000 To $190,479 In 10 Months
08:00am, Monday, 31'st Oct 2022
Investors finally got a decent month in the S&P 500. And some really maximized their gains.
Don't Get Used to Lower Medicare Part B Premiums -- Here's Why
05:30am, Saturday, 29'th Oct 2022
Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future.
Is Biogen a Buy After It Boosted Guidance?
05:52am, Wednesday, 26'th Oct 2022
There's a much bigger story for this biotech than its improved 2022 outlook.
